Recent Publications on Protocatechuic Acid
Protocatechuic Acid Research Related To The Prostate Gland
Protocatechuic acid ameliorates testosterone-induced benign prostatic hyperplasia through the regulation of inflammation and oxidative stress in castrated rats.
J Biochem Mol Toxicol. 2020 Mar 30:e22502. doi: 10.1002/jbt.22502.
https://www.ncbi.nlm.nih.gov/pubmed/32227675
Protocatechuic Acid Research Related To The Brain
Protocatechuic Acid Inhibits Vulnerable Atherosclerotic Lesion Progression in Older Apoe-/- Mice.
J Nutr. 2020 May 1;150(5):1167-1177. doi: 10.1093/jn/nxaa017
https://www.ncbi.nlm.nih.gov/pubmed/32047914
Kinga Krzysztoforska, Dagmara Mirowska-Guzel, Ewa Widy-Tyszkiewicz. Pharmacologi cal effects of protocatechuic acid and its therapeutic potential in neurodegenerative diseases:
Review on the basis of in vitro and in vivo studies in rodents and humans. Nutritional Neuroscience 2019, 22 (2) , 72-82. DOI: 10.1080/1028415X.2017.1354543.
Protocatechuic Acid Research Related To Blood Pressure
Antihypertensive and antioxidant effects of protocatechuic acid in deoxycorticosterone acetate-salt hypertensive rats.
Abstract
Protocatechuic acid (PCA) is a natural antioxidant with beneficial cardiovascular properties. In this study, the effect of supplementation with PCA was investigated in deoxycorticosterone acetate (DOCA)-salt hypertension. Male Wistar rats received DOCA (25 mg/kg, s.c.) twice weekly and 1% NaCl in drinking water and simultaneously treated with PCA (50, 100 and 200 mg/kg, p.o.) for 4 weeks. Systolic blood pressure (SBP) was detected using tail-cuff method. Electrolytes including Na+, K+ and chloride, catalase activity, glutathione, total antioxidant capacity, malondialdehyde (MDA) and hydroperoxides concentration were measured in serum samples. Body and organs weight, water intake and, kidney and heart histopathology were also evaluated. Administration of PCA reversed the changes caused by DOCA-salt approximately at all doses. At the lowest dose, PCA significantly decreased SBP (132.5 ± 4.0 vs 152.3 ± 4.5 mmHg, P < .05), serum sodium (138.5 ± 1.52 vs 141 ± 1.50, P < .05) and chloride level (101.6 ± 1.47 vs 110 ± 1.39, P < .01) and raised serum potassium level (3.8 ± 0.09 vs 3.1 ± 0.17, P < .05) compared with DOCA-salt hypertensive rats. PCA increased serum catalase activity, total antioxidant capacity and glutathione concentration and reduced MDA and hydroperoxides levels. PCA also improved organ weight changes, reduced water intake and moderately prevented histopathological changes of kidney and heart upon DOCA-salt administration. The present study indicates the antihypertensive and antioxidant effects of PCA against DOCA-salt hypertension.